inositol has been researched along with Hyperandrogenism in 9 studies
Inositol: An isomer of glucose that has traditionally been considered to be a B vitamin although it has an uncertain status as a vitamin and a deficiency syndrome has not been identified in man. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1379) Inositol phospholipids are important in signal transduction.
inositol : Any cyclohexane-1,2,3,4,5,6-hexol.
1D-chiro-inositol : Belonging to the inositol family of compounds, D-chiro-inositol (DCI) is an isomer of glucose. It is an important secondary messenger in insulin signal transduction.
muco-inositol : An inositol that is cyclohexane-1,2,3,4,5,6-hexol having a (1R,2R,3r,4R,5S,6r)-configuration.
Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this study demonstrated a good efficacy of both treatments, although in the group treated with the combination of myo-inositol/monacolin K improvement in lipids and hyperandrogenism were significantly better." | 7.79 | [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women]. ( Cappelli, V; De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC, 2013) |
| "This new myo-inositol, monacolin K and lipoic acid association contains appropriate substances to contrast various etiopathogenic elements responsible for the onset of PCOS and the symptoms of hyperandrogenism and dyslipidemia related to it." | 5.20 | Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. ( Cappelli, V; De Leo, V; Di Sabatino, A; Massaro, MG; Morgante, G, 2015) |
| "Myo-inositol and D-chiro-inositol are capable of improving the ovarian function and metabolism of polycystic ovary syndrome (PCOS) patients." | 5.19 | Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. ( Barbaro, L; Laganà , AS; Pizzo, A, 2014) |
| "The results of this study demonstrated a good efficacy of both treatments, although in the group treated with the combination of myo-inositol/monacolin K improvement in lipids and hyperandrogenism were significantly better." | 3.79 | [Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women]. ( Cappelli, V; De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Menichini, D | 1 |
| Ughetti, C | 1 |
| Monari, F | 1 |
| Di Vinci, PL | 1 |
| Neri, I | 1 |
| Facchinetti, F | 1 |
| Fedeli, V | 1 |
| Catizone, A | 1 |
| Querqui, A | 1 |
| Unfer, V | 2 |
| Bizzarri, M | 1 |
| Iervolino, M | 1 |
| Lepore, E | 1 |
| Forte, G | 1 |
| Laganà , AS | 2 |
| Buzzaccarini, G | 1 |
| Morgante, G | 3 |
| Massaro, MG | 2 |
| Di Sabatino, A | 3 |
| Cappelli, V | 3 |
| De Leo, V | 3 |
| Stracquadanio, M | 1 |
| Ciotta, L | 1 |
| Palumbo, MA | 1 |
| Musacchio, MC | 1 |
| Pizzo, A | 1 |
| Barbaro, L | 1 |
| Genazzani, AD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial)[NCT05701813] | 56 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for inositol and Hyperandrogenism
| Article | Year |
|---|---|
Nutraceuticals and polycystic ovary syndrome: a systematic review of the literature.
Topics: Dietary Supplements; Female; Glucose; Humans; Hyperandrogenism; Inositol; Polycystic Ovary Syndrome; | 2022 |
The Role of Inositols in the Hyperandrogenic Phenotypes of PCOS: A Re-Reading of Larner's Results.
Topics: Androgens; Aromatase; Estrogens; Female; Follicle Stimulating Hormone; Humans; Hyperandrogenism; Ino | 2023 |
Natural Molecules in the Management of Polycystic Ovary Syndrome (PCOS): An Analytical Review.
Topics: Ascorbic Acid; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Female; Flavanones; Flavono | 2021 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Inositol as putative integrative treatment for PCOS.
Topics: Female; Humans; Hyperandrogenism; Hyperinsulinism; Inositol; Inositol Phosphates; Insulin; Insulin R | 2016 |
2 trials available for inositol and Hyperandrogenism
| Article | Year |
|---|---|
Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
Topics: Adolescent; Adult; Amenorrhea; Dietary Supplements; Double-Blind Method; Female; Folic Acid; Follicl | 2014 |
Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
Topics: Adult; Antioxidants; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Fem | 2015 |
2 other studies available for inositol and Hyperandrogenism
| Article | Year |
|---|---|
Effects of myo-inositol, gymnemic acid, and L-methylfolate in polycystic ovary syndrome patients.
Topics: Adult; Blood Glucose; Body Mass Index; Body Weight; Drug Therapy, Combination; Female; Humans; Hyper | 2018 |
[Evaluation of the myo-inositol-monacolin K association on hyperandrogenism and on the lipidic metabolism parameters in PCOS women].
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Inositol; Lipid Metabolism; Lova | 2013 |